ReviewMaterials today. Bio2026
Polymeric anti-platelet carriers for the precision-targeting of age-related cardiovascular and cerebrovascular diseases.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global aging population has increased the burden of cardiovascular and cerebrovascular diseases, which remain leading causes of morbidity and mortality worldwide. In their pathogenesis, platelets not only promote thrombus formation but also exert proinflammatory effects that cause extensive inflammatory responses, accelerating atherosclerosis and endothelial dysfunction. Traditional systemic anti-platelet agents face considerable challenges in elderly patients due to the delicate balance between antithrombotic efficacy and bleeding risk. Polymeric anti-platelet carriers alter the risk-benefit balance between antithrombotic efficacy and bleeding complications through local, biomarker-guided drug delivery. This review systematically summarizes platelet dysfunction in age-related cardiovascular and cerebrovascular diseases and corresponding strategies for constructing precision-targeted polymeric carriers. We first summarize major platelet-related biomarkers that have emerged as actionable targets, including glycoprotein VI (GPVI), platelet-derived growth factor-B (PDGF-B) and its receptor PDGFR-β, reactive oxygen species (ROS), and disease-associated shear stress. We then review recent advances in surface engineering approaches for targeted delivery, with emphasis on ligand-guided targeting, biomimetic cloaking, and multivalent binding designs. Next, we discuss carrier architectures tailored to improve drug loading and enable controlled release, highlighting stimuli-responsive platforms that exploit thrombotic microenvironmental signals, such as acidic pH, enzyme enrichment, oxidative stress, and shear forces, to trigger site-specific drug liberation. We also outline synergistic strategies that integrate anti-inflammatory and thrombolytic actions with biomimetic features to more effectively manage cardiovascular and cerebrovascular disorders. Finally, we consider future opportunities for polymeric anti-platelet delivery systems, focusing on materials innovation, patient stratification and personalization, and translational considerations that will shape long-term clinical utility. Overall, this review underscores the promise of polymer-based anti-platelet carriers for the prevention and treatment of age-related cardiovascular and cerebrovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.